Crowder Timothy M
Oriel Therapeutics, Inc. PO Box 14087, Research Triangle Park, NC 27709, USA.
Expert Opin Drug Deliv. 2005 May;2(3):579-85. doi: 10.1517/17425247.2.3.579.
Dry powder inhalers (DPIs) have been in use since the 1970s, but it is only within the past few years that their use has constituted > approximately 10% of the inhaler units sold worldwide. Similarly, active DPIs have been in development for more than a decade, but no active device has yet been approved. Oriel is developing an active DPI technology that uses a very simple physical design coupled with a complex knowledge of powder flow and dispersion characterisation. The DPI uses electromechanical vibration with frequencies determined through the analysis of powder flow properties. Results so far have shown highly reproducible, efficient performance. The technology lends itself to both unit-dose and multidose platforms in a targeted cost-effective DPI.
干粉吸入器（DPIs）自20世纪70年代就已投入使用，但直到最近几年，其使用量才占到全球吸入器销售总量的约10%以上。同样，主动式干粉吸入器已经研发了十多年，但尚未有主动式装置获得批准。奥瑞尔公司正在开发一种主动式干粉吸入器技术，该技术采用非常简单的物理设计，并结合了对粉末流动和分散特性的复杂认识。这种干粉吸入器利用机电振动，其频率通过对粉末流动特性的分析来确定。到目前为止，结果显示出高度可重复、高效的性能。该技术适用于单位剂量和多剂量平台，能打造出具有成本效益的靶向干粉吸入器。
